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Abstract 
Background: Osteonecrosis of the jaw (ONJ) is a rare but serious adverse drug effect linked to long-term and/
or high-dose exposure to nitrogen-bisphosphonates (N-BP), the standard of care for the treatment of bone fragil-
ity disorders. The mechanism leading to bisphosphonate-associated ONJ (BAONJ) is unclear and optimal treatment 
strategies are lacking. Recent evidence suggests that BAONJ may be linked to drug-induced immune dysfunction, 
possibly associated with increased susceptibility to infections in the oral cavity. The objective of this investigation was 
to comprehensively assess the relationship linking immune function, N-BP exposure, the oral microbiome and ONJ 
susceptibility.
Methods: Leukocyte gene expression of factors important for immunity, wound healing and barrier function were 
assessed by real-time quantitative PCR and the oral microbiome was characterized by 454 pyrosequencing of the 16S 
rRNA gene in 93 subjects stratified by N-BP exposure and a history of ONJ.
Results: There were marked differences in the systemic expression of genes regulating immune and barrier functions 
including RANK (p = 0.007), aryl hydrocarbon receptor (AHR, p < 0.001), and FGF9 (p < 0.001), which were collectively 
up-regulated in individuals exposed to N-BP without ONJ relative to treatment controls. In contrast, the expression 
levels of these same genes were significantly down-regulated in those who had experienced BAONJ. Surprisingly, the 
oral microbiome composition was not directly linked to either BAONJ or N-BP exposure, rather the systemic leukocyte 
expression levels of RANK, TNFA and AHR each explained 9% (p = 0.04), 12% (p = 0.01), and 7% (p = 0.03) of the oral 
bacterial beta diversity.
Conclusions: The oral microbiome is unlikely causative of ONJ, rather individuals with BAONJ lacked immune resil-
iency which impaired their capacity to respond adequately to the immunological stress of N-BP treatment. This may 
be the common factor linking N-BP and anti-RANK agents to ONJ in at-risk individuals. Preventive and/or therapeutic 
strategies should target the wound healing deficits present in those with ONJ.
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Background
Since their approval for clinical use in the mid-1980’s, 
nitrogen-bisphosphonates (N-BP) have become the 
established treatment for diseases of excess bone resorp-
tion such as osteoporosis, Paget’s disease and cancer-
associated bone disease. N-BP are structural analogues 
to pyrophosphates, which confers their ability to bind to 
hydroxyapatite crystals of bone surfaces [1]. The potent 
anti-bone resorption property of N-BP is mediated 
through their inhibition of a key enzyme in the meva-
lonate pathway for isoprenoid biosynthesis, farnesyl 
pyrophosphate synthase (FPPS) [2, 3], which results in 
the prevention of protein prenylation necessary for oste-
oclast function [4].
Despite clinical efficacy for the prevention of certain 
types of fragility fractures [5, 6], high-dose or long-
term N-BP exposure is associated with rare but serious 
drug-related complications such as osteonecrosis of 
the jaw (ONJ) [7, 8]. ONJ appears as a painful lesion of 
exposed necrotic bone in the mandible or maxilla that 
fails to heal within 8  weeks [9]. The exact mechanism 
leading to bisphosphonate-associated ONJ (BAONJ) 
is unknown, but one prevalent theory is that it may be 
induced by the direct toxic effects of the drug on bone 
and soft tissue [10]. However, emerging reports of ONJ 
in patients treated with the new anti-resorptive agent, 
anti-RANKL antibody (denosumab) [11]—a biologic 
with a different mechanism of action, raises doubts that 
BAONJ is primarily a consequence of drug-induced tis-
sue toxicity. Proposed risk factors include periodontal 
disease, smoking, cancer, chemotherapy, glucocorticoid 
use and diabetes [12].
We previously noted that osteoporosis patients treated 
with N-BP tended to become deficient in a unique sub-
set of human peripheral blood innate T cells bearing 
the Vγ9 Vδ2 TCR [13]. This loss was directly correlated 
to the length of time on therapy and was most striking 
in patients receiving the drug intravenously [13]. The 
observed decline of γδ T cells might be at least partially 
due to inhibitory effects of granulocytes on Vγ9 Vδ2 T 
cell activation upon up-take of N-BP [14, 15]. A suppres-
sive effect of granulocytes on human γδ T cell activation 
has been recently observed by other groups as well [16]. 
Patients who had experienced ONJ were largely lacking 
peripheral Vγ9 Vδ2 T cells, but they all additionally had 
co-morbid conditions that could further impair immune 
resiliency [13]. In this study, we evaluated the impact of 
N-BP treatment and the occurrence of BAONJ on leuko-
cyte mRNA expression patterns of genes that are pivotal 
for immunity, wound healing and/or barrier function 
known to be, in part, regulated by γδ T lymphocytes [17–
24]. Collectively, these included RANK, RANKL, TNFA, 
IL17, IFNG, IL1B, FGF9, GMCSF, CTGF, MMP7, MMP9, 
and AHR.
The oral microbiota (and in consequence oral immu-
nity) has been repeatedly postulated to be linked to the 
development of BAONJ [25–27], but there is no com-
pelling evidence showing a direct relationship between 
infection and ONJ pathogenesis [28]. Nevertheless, 
aggressive systemic treatment with antibiotics is usu-
ally part of the therapeutic strategy to manage ONJ. This 
approach appears to have limited impact on the overall 
oral microbial diversity [29], but it potentially provides 
some prophylactic benefit for patients with multiple mye-
loma given N-BP intravenously [30].
The aim of our present study was to define the rela-
tionship linking immune and wound healing resiliency, 
N-BP exposure, the oral microbiome and susceptibility 
to BAONJ to (1) improve identification of those individu-
als at greatest risk for the development of ONJ, and (2) 
provide mechanistic insight into its pathophysiology to 
advance current treatment strategies.
Methods
Study design
This study was approved by the Clinical Ethics Board of 
the Faculty of Medicine of Christian-Albrechts University 
of Kiel (D 411/11) and was conducted in accordance with 
the principles of the Declaration of Helsinki for medical 
research involving human subjects. Patients with osteopo-
rosis who were either N-BP-treatment naive or had been 
on continuous N-BP therapy for various lengths of time 
were invited to participate in the study through a network 
of community physicians in Kiel, Germany. The number 
of subjects in each treatment group was based on our pre-
vious findings on the observable differences in immune 
profiles [13]. The diagnosis and treatment of osteoporo-
sis were based on the guidelines established by the Ger-
man Specialist Organisation for Osteology (Dachverband 
Osteologie, DVO [31]. Exclusion criteria for the osteopo-
rosis cohort included use of strong immuno-modulatory 
drugs such as systemic corticosteroids or other immuno-
suppressive agents, and the presence of any malignancy. 
Patients who had experienced N-BP-associated ONJ 
within the last 2 years were contacted through the Depart-
ment of Oral and Maxillofacial Surgery. The diagnosis of 
BAONJ was based on established guidelines [8]. The only 
exclusion criterion for the BAONJ cohort was being on 
active antibiotic treatment. Additional control subjects 
who were age-matched for the BAONJ cohort were later 
recruited through physician offices and the Department 
of Immunology to account for the potential influence of 
age on the variables assessed. All study subjects provided 
informed written consent.
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Sample collection
Blood collected in EDTA tubes was aliquoted in 200 µl 
and mixed with 800 µl Prisure (Promolgene, Berlin, Ger-
many) and immediately stored at −80°C for subsequent 
RNA extraction, cDNA synthesis and gene expression 
analysis. Isohelix DNA swabs (SK-2S, Biolab products 
GmbH, Bebensee, Germany) were used to obtain micro-
bial DNA by running the swab along the same area of the 
outer gumline of subjects (original instructions provided 
to physicians for uniform oral microbiome sampling is 
provided as Additional file 1). DNA extraction was per-
formed using the Isohelix Buccalyse DNA extraction 
kit (Biolab products GmbH, Bebensee, Germany). The 
extracted DNA was stored at −20°C until analysis.
RNA extraction
RNA extraction was carried out on defrosted blood 
samples using the Prisure reagent (Promolgene, Berlin, 
Germany) following the manufacturer’s protocol. The 
resulting RNA pellet was dissolved in 20  µl diethylpyro-
carbonate-(DEPC-) treated water (Promolgene, Berlin, 
Germany), and RNA concentration was measured using 
the Nanodrop 1000 (Peqlab, Erlangen Germany). The 
remaining RNA was stored at -20°C until cDNA synthesis.
cDNA synthesis
For cDNA synthesis, 200  ng total RNA were tran-
scribed into cDNA, using the TR cDNA synthesis kit 
(AmpTec Hamburg, Germany) with the provided oligo 
dT-V primer. cDNA synthesis was carried out using 
a Thermocycler I (Biometra, Göttingen, Germany) as 
follows: primer and RNA were incubated at 65°C for 
5  min; samples were immediately placed on ice and 
the PCR mix (RT-enzyme, RT-buffer, and dNTPs) was 
added; lastly samples were incubated for 60  min at 
37°C, followed by a denaturation step (10 min at 72°C). 
The resulting cDNAs were purified from the remain-
ing enzyme, buffer, and dNTPs with the provided spin 
columns and stored at −20°C until further analysis.
Real‑time quantitative polymerase chain reaction (RTqPCR)
RTqPCR was performed using a Rotorgene 3000 (Corbett, 
LTF, Wasserburg, Germany). SYBR green-based qPCR 
mix and primers for the housekeeping genes (b-actin, 
beta-2-microglobulin and 18S) were purchased from Pro-
molgene (Berlin, Germany). All PCR reactions were run 
in duplicates using 2.5  µl of the above mentioned cDNA 
(≈10 ng total RNA) in a total reaction volume of 25 µl. PCR 
conditions were as follows: 10  min initial denaturation at 
95°C, followed by 40 cycles of denaturation: 20  s at 95°C, 
annealing 20  s at primer specific annealing temperatures 
(see below), elongation: 20 s at 72°C. After the last cycle, a 
melt curve analysis was performed starting at the primer 
specific annealing temperatures. Unless otherwise indi-
cated, primers were designed using the web-based primer3 
software (http://primer3.wi.mit.edu/) and were synthesized 
by TIB MOLBIOL (Berlin, Germany). The following prim-
ers for the respective genes (annealing temperatures pro-
vided in parenthesis) were assessed: FGF9 sense primer: 
5′-GGCGTGGACAGTGGACTCTACCTC -3′, FGF9 anti-
sense primer: 5′-TTCCCATCCAAGCCTCCATCATA 
C -3′ (56°C) [18]; IFNG sense primer: 5′-TCAGCTCTGC 
ATCGTTTTGG-3, IFNG antisense primer: 5′-GTTCCA 
TTATCCGCTACATCTGAA-3′ (60°C); TNFA sense 
primer: 5′-CTTCTCGAACCCCGAGTGA-3′, TNFα anti-
sense primer: 5′-CCTCTGATGGCACCACCAG-3′ (60°C); 
IL1B sense primer: 5′-CTGTCCTGCGTGTTGAAAGA-3′, 
IL1B antisense primer: 5′-TTGGGTAATTTTTGGG 
ATCTACA-3′ (62°C); IL17 sense primer: 5′-TTAAGG 
CCCCTCAGAGATCA-3′, IL17 antisense primer: 5′-T 
CAGCTCCTTTCTGGGTTGT-3′ (64°C); connective tis-
sue growth factor (CTGF) sense primer: 5′-ACGGCGAG-
GTCATGAAGAAGAACA-3′, CTGF antisense primer: 
5′-TGGGGCTACAGGCAGGTCAGTG-3′ (61°C) [19]; 
RANKL sense primer: 5′-ACCAGCATCAAAATCCCA 
AG3′, RANKL antisense primer: 5′-ATCCAGTAAGG 
AGGGGTTGG-3′ (62°C); RANK sense primer: 5′- AGG 
GAGCATGTGAAGGTGTC-3′, RANK anti sense primer 
5′-TGCTGACCAATGAGAGCATC-3′ (64°C); MMP7 sense 
primer: 5′-TCAGGCAGAACATCCATT-3′, MMP7 anti-
sense primer: 5′-TTTATTGACATCTACCCAACTGC-3′ 
(50°C) [20]; MMP9 sense primer: 5′-CGCGGGCGGTGA 
TT G ACGAC-3′, MMP9 antisense primer: 5′-GTGGTG 
CAGGCGGAGTAGGATTGG-3′ (63°C) [20]; GMCSF 
sense primer: 5′-TGCTCTTGGGCACTGTGG-3′, GMCSF 
antisense primer: 5′- CCCTGCTTGTACAGCTCCAG-3′ 
(60°C) and aryl hydrocarbon receptor (AHR) sense primer: 
5′-GTTGGACGTCAGCAAGTTCA-3′, AHR antisense 
primer: 5′-TGGTGCCCAGAATAATGTGA-3′ (60°C). 
Threshold levels for Ct-determination were chosen manually. 
Data analysis was performed according to the ∆Ct-method 
using the mean Ct value of three housekeeping genes [32].
Microbiota sequencing and sequence filtering
The V1–V2 region of the bacterial 16S rRNA gene was 
amplified from the DNA extracted from mouth swabs 
using using primers 27F (CTATGCGCCTTGCCAGCC 
CGCTCAGTCAGAGTTTGATCCTGGCTCAG-3′) 
and 338R (5′CGTATCGCCTCCCTCGCGCCATCA 
G X X X X X X X X X XC ATG C TG C C TC C C G TAG G 
AGT-3′), where XXXX denotes a 10nt index sequences 
and the italicised sequences are adapters for the 454 
Roche platform. Amplification was carried out using 
the Phusion Hot Start DNA Polymerase II (Finnzymes, 
Espoo, Finland) with the following PCR conditions: ini-
tial denaturation for 30 s at 98°C; 30 cycles of 9 s at 98°C, 
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30 s at 55°C, and 30 s at 72°C; final extension for 10 min 
at 72°C [33]. PCR products were then processed on a 
454-FLX sequencer and output sequences were filtered 
according to quality (average >25) and length (minimum 
length 250, maximum length 400) using Mothur [34]. 
We obtained an average of 2,436 high quality reads per 
sample (minimum number was 955). To standardize the 
sample size, a subset of ~1000 reads was selected for each 
sample for the oral microbiota analysis, as suggested by 
Hamady et  al. [35]. Chimera detection was performed 
using Uchime [36] against recommended databases. 
Classification of the sequences was carried out using 
RDP classifier [37] and taxonomical consensus was cre-
ated for all samples from the phylum to genus level.
Ecological analysis
Bray-Curtis and Jaccard dissimilarities were used to ana-
lyze beta diversity, and tests for differences among groups 
of samples were performed using constrained analysis of 
principle coordinates [38] (function “capscale”) and anal-
ysis of dissimilarity (function “adonis”) in the ‘VEGAN’ R 
package, R Development Core Team 2011 [39].
Statistical analysis
Calculations for the fold change in gene expression 
assessed by RTqPCR used for graphical representation of 
the data were based on the mathematical model previously 
described [40]. Normalized ∆Ct values for each gene were 
checked for skewness and kurtosis. RANK, RANKL, CTGF, 
MMP7, MMP9 and AHR showed a right skewed distribu-
tion and were log10 transformed for subsequent statistical 
analysis. Group differences in relative gene expression were 
assessed by ANOVA. Tukey’s HSD post hoc test was used 
to determine individual mean differences between cohorts 
while correcting for multiple comparisons. Pearson’s cor-
relation was used to assess associations among variables, 
and multiple linear regression models were built for genes 
showing strong correlations with length of time on N-BP 
therapy with age included in the model. Generalized linear 
models were built to assess the relationship between leu-
kocyte gene expression and bacterial taxa, while the Vegan 
software “envfit” function was used to assess the influence 
of the of leukocyte gene expression levels on oral bacterial 
communities. Data analysis was performed using SPSS ver-
sion 20 (SPSS Inc., Chicago, IL, USA), and bacterial com-
munity comparisons were carried out using the “Vegan” R 
package (R Development Core Team 2011) [39].
Results
Study subjects
The study included 93 subjects stratified by exposure 
to N-BP and the occurrence of BAONJ within the last 
2  years; detailed characteristics of study participants 
are provided in Table  1. Seventy-five of the 79 subjects 
Table 1 Characteristics of  study subjects (n =  93) stratified by  N-BP exposure and  the occurrence of  bisphosphonate-
associated osteonecrosis of the jaw (ONJ)
Group N Mean age 
(years ± SD)
Median length of time on N‑BP 
therapy (days, range)
Characteristics and type of N‑BP therapy
N-BP treatment naïve controls 26 66.4 ± 10.0 NA 18 with osteoporosis (mean age 72.1 ± 6)
8 Postmenopausal women without osteo-
porosis (mean age 53.6 ± 2)
Oral N-BP 30 74.1 ± 5.7 90 (1,764) 90% On oral alendronate (70 mg/week); 
10% on oral ibandronate (150 mg/
months)
Intravenous N-BP 31 73.2 ± 5.5 813 (1,982) All on intravenous ibandronate (3 mg/
months)
ONJ 6 61.3 ± 12.5 1,113 (1,282) 1 Woman (85 yrs) was being treated with 
5 mg/year intravenous zoledronate (had 
received 2 shots) for osteoporosis, previ-
ously had a blood malignancy and was on 
prednisone
1 Woman on systemic corticosteroids and 
mycophenolate mofetil on oral aledronate 
(70 mg/week) for 3.5 years
1 Woman on interferon therapy for hepatitis 
B & C on oral aledronate (70 mg/week) 
for 5 years
3 Women who had been treated for 
metastatic breast cancer; all on 4 mg/
months intravenous zoledronate (from 1.4 
to 2.8 years)
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(95%) with osteoporosis were postmenopausal women 
(plus 4 men with age-related osteoporosis), as were the 
6 individuals who had previously been diagnosed with 
BAONJ and the 8 additional controls included for age-
matching the slightly younger members of the BAONJ 
cohort. This reduced variance due to ovarian hormones 
on the immune and wound healing factors investigated. 
The subjects who had experienced BAONJ were sampled 
a median of 375 (range 1–606) days after diagnosis and 
treatment for BAONJ, and the majority continued N-BP 
treatment after BAONJ diagnosis.
Leukocyte gene expression of factors important 
for immunity, wound healing and barrier function
N-BP exposure has a marked impact on the immune 
system largely through their ability to activate a unique 
subset of human peripheral blood γδ T cells that bear the 
Vγ9 Vδ2 TCR [13, 41]. Previously it was shown the main 
consistent difference in the immune profile of those who 
had developed BAONJ was the almost complete loss of 
these cells in circulation, presumably through chronic or 
high-dose exposure to N-BP [13]. We therefore evalu-
ated the impact of N-BP treatment and the occurrence of 
BAONJ on leukocyte mRNA expression patterns of genes 
that are pivotal for immunity, wound healing and/or bar-
rier function (Figure 1) [17–24]. All individuals who had 
experienced BAONJ were conspicuously deficient in the 
expression of a specific subset of these factors—which 
included receptor activator of nuclear factor-κB (RANK), 
RANK-ligand (RANKL), tumor necrosis factor-alpha 
(TNFA), fibroblast growth factor-9 (FGF9), granulo-
cyte–macrophage colony stimulatory factor (GMCSF), 
connective tissue growth factor (CTGF), matrix metal-
loproteinase-7 (MMP7), and the aryl hydrocarbon recep-
tor (AHR); Figure 1 and Table 2. In contrast, individuals 
on N-BP treatment without a history of ONJ tended to 
up-regulate the expression of these same genes relative 
to treatment naive controls, and this effect was greatest 
in those on intravenous N-BP. Multiple linear regression 
analysis performed only on the osteoporosis cohort with-
out a history of ONJ (n =  79) indicated that the length 
of time on N-BP therapy, but not age, was significantly 
linked to both higher RANK (β = 0.233, p = 0.045) and 
AHR (β = 0.247, p = 0.032) gene expression.
Visualizing the mRNA expression of these differen-
tially regulated genes on a scatter plot matrix shows that 
most are highly correlated, and in the treatment control 
subjects, the inter-individual expression pattern is rela-
tively diverse (Figure 2, top panel). In contrast, exposure 
to N-BP, especially intravenous treatment, noticeably 
reduced this inter-individual variance and shifted the 
gene expression to a highly clustered pattern for each 
factor (Figure 2, bottom panel). However, those who had 
experienced BAONJ were clearly differentiated as a sepa-
rate subset who failed to respond similarly to N-BP treat-
ment (Figure 2, bottom panel).
Composition of the oral microbiota in relation to N‑BP 
exposure and the development of BAONJ
The composition of the oral microbiome was assessed by 
454 pyrosequencing of the bacterial 16S rRNA gene, and 
a subset of 1,000 reads was selected for each sample for 
the analysis to standardize sample size [35]. The microbi-
ome composition at phylum and genus level is shown in 
Figure 1 Relative leukocyte expression of genes important for immunity, wound healing and barrier function in subjects grouped by type of N-BP 
exposure (n = 30 oral, n = 31 intravenous) and recent history of osteonecrosis of the jaw (ONJ, n = 6). Data presented are the fold change in gene 
expression relative to the N-BP-treatment naive controls (n = 26). Significant overall group differences were observed for RANK (p = 0.007), RANKL 
(p = 0.026), TNFA (p = 0.001), FGF9 (p < 0.001), GMCSF (p = 0.001), CTGF (p = 0.013), MMP7, and AHR (p < 0.001). The greatest mean difference in 
each case was between the intravenously N-BP treated subjects and those who had experienced ONJ with the latter consistently having the lowest 
levels of these genes relative to others. Only for the mRNA levels of MMP7 was the main difference only between the intravenous N-BP and the ONJ 
cohorts as the expression levels of oral N-BP subjects and treatment controls did not differ statistically in comparison to any other group. The actual 
∆CT values are presented in the Table 2.
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Figure 3 for each cohort. Subjects who had experienced 
BAONJ had the highest mean relative abundance of Fir-
micutes (71.32 versus 55.31–60.70%), which paralleled 
their higher abundance of Streptococcus (the major mem-
ber of Firmicutes in the oral microbiome). Consequently, 
those who had experienced BAONJ also had lower Pro-
teobacteria (16.93 versus 22.42–25.21%). However, these 
differences were not statistically significant and no obvi-
ous differences in other phyla were detected. These find-
ings were similar when the analysis was performed with 
age-matching, with the exception the higher Strepto-
coccus abundance was more pronounced in the BAONJ 
group relative to controls. For alpha diversities (micro-
biome composition richness and diversity), the BAONJ 
cohort had the lowest averages based on genus-level 
composition, including the richness estimator Chao1, 
evenness estimator, Shannon, as well as diversity estima-
tor Simpson’s index (Figure 4).
In the context of bacterial communities, beta diversity 
refers to the extent to which taxa differ between groups. 
These differences may be either quantitative—taking 
abundances of each taxa into account (Bray-Curtis dis-
similarity), or qualitative and based on the presence/
absence of a given group (Jaccard dissimilarity). Using 
analysis of dissimilarity (function “adonis”) [39] that 
determines if intra-group dissimilarity are significantly 
lower than that of inter-group, we estimated whether oral 
bacterial communities differ among control groups, ONJ 
patients and patients with different N-BP exposures. In 
summary, neither of the dissimilarity measures of beta 
diversity showed any significant differences on the overall 
composition of bacterial communities based on stratifi-
cation by N-BP exposure and a history of BAONJ (Bray-
Curtis dissimilarity: adonis r = 0.021, p = 0.856; Jaccard 
dissimilarity: adonis r = 0.020, p = 0.936); and no signifi-
cance was found even when comparing oral microbiota 
from age-matched controls and BAONJ patients (Bray-
Curtis dissimilarity: adonis r = 0.043, p = 0.718; Jaccard 
dissimilarity: adonis r = 0.050, p = 0.694).
The relationship between the oral microbiome 
and leukocyte gene expression
The composition of the oral microbiota was observed 
to be strongly influenced by the peripheral blood leu-
kocyte expression levels of a specific subset of immune 
and stress resiliency genes. RANK, TNFA and AHR 
each explained 9% (p  =  0.04), 12% (p  =  0.01), and 7% 
(p =  0.03) of the variance observed in the quantitative 
abundance of the bacterial groups. RANK and AHR 
expression also significantly contributed to qualita-
tive differences of the oral microbiome across individu-
als. Figure  5 and Table  3 provides the Bray-Curtis and 
Table 2 ΔCt values of  the systemic expression of  genes important for  immunity, wound healing and  barrier function 
in subjects (N = 93) stratified by exposure to N-BP and the occurrence of N-BP-associated osteonecrosis of the jaw (ONJ)
∆Ct values decrease with increased gene expression; lower values correspond to greater gene expression and higher values to lower gene expression.
Tukey HSD post hoc test: * significantly different from controls, p < 0.05; ** significantly different from controls, p < 0.01; *** significantly different from controls, 
p < 0.005; ^ significantly different from ONJ, p < 0.05; ^^ significantly different from ONJ, p < 0.01. The differences between the N-BP treatment groups and ONJ are 
only shown for factors where there was no significant difference with the control group. The greatest differences were observed between N-BP treated groups without 
a history of ONJ and those with ONJ.
i.v. intravenous.
a Data are log10 transformed.
Controls (n = 26) Oral N‑BP (n = 30) i.v. N‑BP* (n = 31) ONJ (n = 6) p value
Cytokines
 RANKa 0.95 ± 0.09 0.95 ± 0.03 0.94 ± 0.06 1.0 ± 0.13* 0.026
 RANKLa 1.0 ± 0.08 0.98 ± 0.04^ 0.97 ± 0.05^^ 1.1 ± 0.1 0.007
 TNFA 8.1 ± 1.4 7.6 ± 1.3 7.5 ± 1.8 10.2 ± 1.7 0.001
 IL17 12.6 ± 1.6 13.4 ± 0.97 12.8 ± 1.1 13.3 ± 3.0 0.129
 IFNG 13.8 ± 4.5 14.8 ± 3.9 15.5 ± 3.0 11.9 ± 1.3 0.109
 IL1B 10.8 ± 1.4 10.7 ± 1.1 10.7 ± 0.96 10.5 ± 1.1 0.942
Growth and wound healing factors
 FGF9 11.3 ± 1.8 10.7 ± 0.8 10.1 ± 1.1*** 12.9 ± 0.9* <0.001
 GMCSF 14.7 ± 1.6 14.2 ± 1.1 14.0 ± 1.3 16.4 ± 1.7* 0.001
 CTGFa 0.86 ± 0.14 0.79 ± 0.10 0.80 ± 0.11 0.93 ± 0.14 0.013
 MMP7a 0.86 ± 0.08 0.85 ± 0.05 0.84 ± 0.08^ 0.93 ± 0.16 0.040
 MMP9a 0.96 ± 0.07 0.95 ± 0.10 0.96 ± 0.09 0.92 ± 0.10 0.611
Response to challenge (endogenous or exogenous)
 AHR2 0.93 ± 0.06 0.90 ± 0.03 0.89 ± 0.05* 1.0 ± 0.10** <0.001
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Figure 2 Scatter plot matrix showing the relationship amongst genes found to be differentially expressed in ONJ subjects. Top panel N-BP treat-
ment naive controls show large inter-individual variance in the leukocyte expression levels of the immune and wound healing genes, which show 
a high degree of correlation. Bottom panel intravenous N-BP exposure (green) perceptibly reduced within-group variance in expression levels which 
were shifted to being highly clustered; ONJ cases (purple), however, clearly failed to respond similarly to N-BP exposure and the immune and wound 
healing gene expression levels remained markedly reduced. Note- data represent the actual normalized Ct values, thus higher values moving left to 
right within the matrix correspond to lower gene expression. Statistical differences between groups are reported in Table 2.
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Jaccard dissimilarity r2 values corresponding to the 
relationship between the gene expression levels and the 
composition of the oral microbiome. The abundance of 
Streptococcus was inversely related to RANK (r2 = 0.13, 
p =  0.0002) and AHR (r2 =  0.010, p =  0.0011) expres-
sion. In contrast, the abundance of Fusobacterium was 
positively associated to leukocyte RANK expression 
(r2 = 0.044, p = 0.024).
Discussion
Serious adverse drug reactions often take several years to 
come to light after formal approval for clinical use [12]. 
Figure 3 Oral microbiota profile of individuals stratified by N-BP exposure and history of N-BP-associated osteonecrosis of the jaw (ONJ). a At the 
phylum level, Firmicutes (59.02%) and Proteobacteria (24.27%) were the most prominent oral bacterial communities, followed by Bacteroidetes 
(7.82%), Actinobacteria (5.21%), Fusobacteria (2.35%) and TM7 (1.04%), an uncultured candidate division. The remaining phyla were <1% of the com-
posite communities. b At the level of genera, Streptococcus (43.11%), Haemophilus (13.29%), Veillonella (12.68%), Neisseria (6.49%), Prevotella (4.28%), 
Rothia (3.21%) and unclassified Prevotellaceae (2.55%) were the most abundant genera, with the remainder having <2.5% average abundance. 
Variations in the composition of the oral microbiome between groups were not statistically different.
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The first published reports on BAONJ came out in 2003 
[42]—more than a decade after the widespread clinical 
application of N-BP for a broad range of bone fragility 
disorders. The pathophysiological mechanism leading 
to BAONJ has been elusive, which has prevented the 
ability to clearly identify those specifically at risk and 
the implementation of effective preventative strategies. 
ONJ remains a significant challenge to treat and is usu-
ally dealt with surgically with a short-course of antibiot-
ics. In our experience, multiple surgical attempts may be 
required with 40–50% of cases failing to heal or suffer-
ing a reoccurrence, which is similar to other published 
reports on treatment outcomes [43].
In this investigation, we show the unifying character-
istic of having had a recent history of BAONJ was a sys-
temic deficit in the expression of genes that together play 
a role in enforcing immunity, wound healing and barrier 
function. These genes are normally regulated in part by 
human peripheral blood γδ T cells, which are adversely 
affected in those with BAONJ [13]. Prominently included 
in this group were AHR, TNF family members (RANK, 
RANKL and TNFA) and mediators of wound and tis-
sue healing (FGF9, GMCSF, CTGF, and MMP7). This 
strongly contrasted with our observation that N-BP 
exposure normally increased the mean expression levels 
of these same factors and reduced inter-individual vari-
ation in subjects with osteoporosis. In the latter group, 
the length of time on N-BP therapy, but not age, was sig-
nificantly linked to increased leukocyte RANK and AHR 
expression, which is congruent with the notion that N-BP 
exposure exerts a stress on the immune system [44]. 
This finding may also explain the occurrence of ONJ in 
patients treated with anti-RANKL antibody [11], which 
similarly taxes the same immune-bone axis. RANK, often 
Figure 4 Alpha diversity measures of the plaque microbiome. Chao1 richness estimations (a), Shannon evenness (b) and Simpson’s diversity 
measures (c) are shown for each group. No significant differences can be found among all groups, nor ONJ group vs Control group, N-BP oral and 
N-BP IV group.
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Figure 5 Systemic gene expression levels of RANK and AHR explain part of the variation observed in the oral microbiome. Ordinations of all micro-
bial communities are plotted using principal coordinates analysis (capscale) based on Bray-Curtis dissimilarities. The contour of RANK (upper panel) 
and AHR (lower panel) gene expression levels are average values calculated using a multi-dimensional linear model in odisurf, and arrows indicate 
the direction of increasing gene expression.
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expressed on cells of monocytic lineage and osteoclasts, 
and its receptor, RANKL (also known as TRANCE; 
TNF-related activation induced cytokine), expressed on 
activated T cells and osteoblasts, play a central role in 
both bone remodeling and immune homeostasis, and 
the respective signaling cascade leads to activation of 
the NF-κB pathway [45, 46]. AHR, a transcription fac-
tor pivotal for xenobiotic metabolism, also cooperates 
in signaling through NF-κB to promote dendritic cell 
maturation [47], underscoring the highly integrated sys-
tems governing stress adaptation and immune regulation. 
AHR activity is an essential requirement for intraepithe-
lial lymphocytes of the gut, particularly γδ T cells, and its 
deficiency resulted in the loss of control over microbial 
load and composition and epithelial cell turnover [22]. 
Furthermore, AHR can promote the expression of FGF9 
[48], which was one of the most conspicuously deficient 
factors in those who had experienced BAONJ. FGF9 is 
a growth factor important for tissue repair that plays a 
prominent role in the development of the neural crest-
derived frontal bones of the skull [49], which makes it a 
promising therapeutic target to promote healing in those 
experiencing BAONJ.
Of note, the oral microbiome was not directly related 
to either N-BP exposure or ONJ status—but was instead 
associated with the gene expression levels of TNF family 
members and AHR. Investigations using a comprehensive 
high resolution metagenomic approach with appropriate 
control groups to assess the role of infection in BAONJ 
have been lacking. A study by Wei et al. utilizing a semi-
quantitative technique based on gene fragmentation anal-
ysis on a denaturing gradient gel to compare the bacterial 
composition of the jawbone of 12 cancer patients (6 with 
BAONJ and 6 without ONJ or exposure to N-BP) found, 
similar to our results, that BAONJ was associated with a 
higher abundance of Streptococcus and lower Fusobacte-
rium—with no other significant differences between the 
two groups [50]. More recently, Pushalkar et al., who sim-
ilarly used denaturing gel analysis, observed that the oral 
microbiome diversity was lower in those who developed 
BAONJ (n = 5) compared to those with periodontal dis-
ease (n = 5) or those with a history of N-BP use without 
ONJ (n = 5) [51]. However, in addition to having a very 
small number of controls, this study failed to match for 
either sex or gender, which are important variables influ-
encing both the microbiome and immune function. Simi-
lar to Wei et al’s study, we observed there was a greater 
abundance of Streptococcus but this change in microbi-
ome composition was related to a reduced expression of 
genes important for barrier function, particularly RANK, 
TNFA and AHR. In contrast, Fusobacterium, a gram-neg-
ative anaerobe and a known contributor to periodontal 
disease, appears to thrive under conditions with higher 
expression of RANK and AHR, which may relate to the 
parallel increase in hypoxia with inflammation [52]. This 
provides clinical evidence that the oral microbiome is 
influenced by the systemic expression levels of these 
genes, and it supports a role for AHR in maintaining oral 
barrier function in humans, as was found to be the case 
for the murine gut [22]. This has important implications 
for the oral health of those who use pharmaceuticals or 
have disorders that exert a chronic pressure on systemic 
immunity.
BAONJ is a rare adverse drug effect of yet undeter-
mined etiology; therefore the number of patients during 
the course of this investigation was limited. However, 
despite the heterogeneous medical history and demo-
graphic background of the ONJ patients included in the 
study, immune impairment (be it inherent or secondary 
to medication) was the primary consistent characteristic 
of its occurrence.
Conclusions
Individuals who experienced BAONJ collectively lacked 
immune resiliency and normal barrier function as evi-
denced by their compromised gene expression levels for 
a number of pivotal factors—including RANK, AHR and 
FGF9. This reduced capacity to respond to challenge 
would not only affect their interaction with the nor-
mal microbiome, but it would also reduce their ability to 
withstand the significant added stress of N-BP treatment, 
which induced the up-regulation of these same stress 
Table 3 The relationship between  quantitative (Bray-Cur-
tis Dissimilarity) and  qualitative (Jaccard Dissimilarity) 
beta diversity measures of  the oral microbiome and  the 
expression of  genes related to  immune system, wound 
healing and barrier function
r2 for Bray‑Curtis p value r2 for Jaccard p value
Cytokines
 RANK 0.0872 0.040 0.0723 0.028
 RANKL 0.0611 0.089 0.0395 0.171
 TNFA 0.1169 0.010 0.0176 0.542
 IL17 0.0073 0.810 0.0138 0.573
 IFNG 0.0256 0.419 0.0305 0.366
 IL1B 0.0677 0.095 0.0364 0.192
Growth and wound healing factors
 FGF9 0.0271 0.281 0.0298 0.247
 GMCSF 0.0391 0.168 0.0438 0.140
 CTGF 0.0319 0.230 0.0404 0.144
 MMP7 0.0235 0.328 0.0267 0.263
 MMP9 0.0177 0.462 0.0245 0.298
Response to challenge (endogenous or exogenous)
 AHR 0.0721 0.027 0.0768 0.034
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response genes in those with normal immune function. 
This may be the common link between N-BP and anti-
RANK agents and the development of ONJ in at-risk indi-
viduals. Intriguingly, the oral microbiome composition 
was strongly associated with the gene expression levels 
of RANK and AHR in leukocytes, but appears to be only 
indirectly linked to BAONJ and N-BP exposure. These 
results suggest those with either acquired (i.e., through 
drugs or illness) or inherent immune dysfunction are 
most at risk for the development of BAONJ and caution 
should be used when exposing such subjects to high-dose 
or long-term N-BP therapy. Preventative and treatment 
strategies should focus on targeting the immune and 
wound healing deficits observed in these patients.
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